Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Don’t edit the human germ line

Nature volume 519, pages 410–411 (2015)Cite this article

Subjects

Heritable human genetic modifications pose serious risks, and the therapeutic benefits are tenuous, warn Edward Lanphier, Fyodor Urnov and colleagues.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Regalado, A. MIT Tech. Rev. http://go.nature.com/2n2nfl (2015).

  2. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang. H. S. & Gregory, P. D. Nature Rev. Genet. 11, 636–646 (2010).

    Article  CAS  Google Scholar 

  3. Carroll, D. Annu. Rev. Biochem. 83, 409–439 (2014).

    Article  CAS  Google Scholar 

  4. Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).

    Article  CAS  Google Scholar 

  5. Yoshimi, K., Kaneko, T., Voigt, B. & Mashimo, T. Nature Commun. 5, 4240 (2014).

    Article  ADS  CAS  Google Scholar 

  6. Heo, T. Y. et al. Stem Cells Dev. 24, 393–402 (2015).

    Article  CAS  Google Scholar 

  7. Han, H. et al. Front. Agr. Sci. Eng. 1, 2–5 (2014).

    Google Scholar 

  8. Kang, Q. et al. in Proc. 10th World Congr. Genet. Appl. Livestock Prod. http://go.nature.com/6mtz2d (2014).

    Google Scholar 

  9. Geurts, A. M. Science. 325, 433 (2009).

    Article  ADS  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edward Lanphier is president and chief executive officer of Sangamo BioSciences in Richmond, California, USA, and chairman of the Alliance for Regenerative Medicine in Washington DC, USA.,

    Edward Lanphier

  2. Fyodor Urnov is senior scientist at Sangamo BioSciences in Richmond, California, USA.,

    Fyodor Urnov

  3. Sarah Ehlen Haecker is director of technology sections at the Alliance for Regenerative Medicine in Washington DC, USA.,

    Sarah Ehlen Haecker

  4. Michael Werner is executive director of the Alliance for Regenerative Medicine in Washington DC, USA.,

    Michael Werner

  5. Joanna Smolenski is a PhD student in philosophy at the Graduate Center of the City University of New York, New York, USA.,

    Joanna Smolenski

Authors
  1. Edward Lanphier
    View author publications

    Search author on:PubMed Google Scholar

  2. Fyodor Urnov
    View author publications

    Search author on:PubMed Google Scholar

  3. Sarah Ehlen Haecker
    View author publications

    Search author on:PubMed Google Scholar

  4. Michael Werner
    View author publications

    Search author on:PubMed Google Scholar

  5. Joanna Smolenski
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Edward Lanphier.

Ethics declarations

Competing interests

E.L. and F.U. are employees of Sangamo BioSciences, Inc.

Additional information

Tweet Facebook LinkedIn weibo

Related links

Related links

Related links in Nature Research

Related external links

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lanphier, E., Urnov, F., Haecker, S. et al. Don’t edit the human germ line. Nature 519, 410–411 (2015). https://doi.org/10.1038/519410a

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/519410a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research